It is known that MMR-deficient cells are resistant or acquire resistance to common chemotherapeutic drugs, such as 5-FU, used against colorectal cancer, or cisplatin and carboplatin, widely used for the treatment of ovarian cancers [225,226]. The gene discussed is MRC1; the disease is ovarian carcinoma.